Drug Profile
MTC 1203
Alternative Names: MTC-1203Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Mitoconix Bio
- Class Neuroprotectants; Peptides
- Mechanism of Action Mitochondrial protein inhibitors; Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease; Neurodegenerative disorders
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Huntington's-disease in Israel
- 28 Aug 2021 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Israel
- 04 Jul 2017 Preclinical trials in Huntington's disease in Israel before July 2017 (FutuRx website, July 2017)